Our award-winning reporting has moved

Context provides news and analysis on three of the world’s most critical issues:

climate change, the impact of technology on society, and inclusive economies.

Ensuring global COVID-19 vaccine access seen worth billions to rich nations

by Sonia Elks | @SoniaElks | Thomson Reuters Foundation
Thursday, 3 December 2020 14:07 GMT

A healthcare worker wearing personal protective equipment (PPE) waits to test residents during a medical campaign for the coronavirus disease (COVID-19) at a slum area in Mumbai, India, June 30, 2020. REUTERS/Francis Mascarenhas

Image Caption and Rights Information

Ten wealthy countries would see economic gains of up to $466 billion by 2025 if poorer nations get access to coronavirus jabs, analysis shows

By Sonia Elks

LONDON, Dec 3 (Thomson Reuters Foundation) - Rich nations stand to lose hundreds of billions of dollars in economic output over the next five years if poorer countries do not get equal access to COVID-19 vaccines, a report said on Thursday as concerns grow about "vaccine nationalism".

As the World Health Organisation (WHO) seeks to plug funding gaps in its ACT Accelerator programme for global COVID-19 treatments, researchers said their findings showed there was a financial - as well as a moral - case for ensuring equal access.

"Governments are increasingly focusing on investments that can help their own economies to rebound," said Hassan Damluji, deputy director at the Bill & Melinda Gates Foundation, which commissioned the report by the Eurasia Group research firm.

"The ACT Accelerator is precisely one of those investments. It is both the right thing to do, and an investment that will pay dividends by bringing the global economy back from the brink, benefiting all nations."

The ACT Accelerator (Access to COVID-19 Tools) is an international programme working to support the development of COVID-19 tests, treatments and vaccines and ensure they are available around the world.

As nations prepare to roll out mass COVID-19 vaccination programmes, with Britain becoming the first to approve a vaccine for use this week, there has been concern that "vaccine nationalism" could see poorer countries left behind.

The WHO says the programme needs $38 billion - of which about $28 billion is still outstanding, without which lower-income countries will not be able to get prompt access to COVID-19 drugs including vaccines.

Thursday's report assessed the economic benefits of ensuring swift, equal global access to vaccines to 10 major economies - Canada, France, Germany, Japan, Qatar, South Korea, Sweden, United Arab Emirates, United Kingdom and the United States.

It found boosts to the global economy as a result meant they stood to gain at least $153 billion in 2020-21, and $466 billion by 2025, in an analysis based on IMF World Economic Outlook forecasts of varying vaccination scenarios.

WHO Director-General Tedros Adhanom Ghebreyesus hailed the report, and said contributing to the ACT Accelerator was "the smart thing for all countries – socially, economically and politically".

Its findings are in line with an earlier study that found wealthy countries stood to lose $119 billion a year through uneven vaccine access, said Andrea Taylor, a researcher at the Duke Global Health Institute's project tracking COVID-19 data.

"It is in the best interests of wealthy nations to invest in equity and it will cost all of us more if we don't, both in terms of mortality and GDP," she told the Thomson Reuters Foundation.

Related stories:

Pfizer, Moderna, AstraZeneca: Which COVID-19 vaccine could reach developing countries first?

COVID-19 vaccine a 'moral moment' for humanity, conference hears

Can coronavirus vaccines reach developing countries?

(Reporting by Sonia Elks @soniaelks; Additional reporting by Thin Lei Win; Editing by Helen Popper. Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers the lives of people around the world who struggle to live freely or fairly. Visit http://news.trust.org)

Our Standards: The Thomson Reuters Trust Principles.